MacroGenics spent the past year selling the last pieces of a fully integrated antibody company and keeping only the discovery engine. The July close of the Rockville manufacturing plant sale to Bora Pharmaceuticals, together with a second Sagard Healthcare royalty check on Incyte's ZYNYZ and two partner milestone receipts, recasts the equity as a cash-backed clinical option rather than a small commercial-plus-contract-manufacturer hybrid. What changed is not a surprise efficacy print. It is a capital-structure choice. Management converted hard assets and residual royalty streams into a multi-year runway and a roughly one-hundred-forty-person organization pointed at antibody-drug conjugates and T-cell engagers.
The tension sits in the income statement, not the cash headline. Continuing operations still lose money even after research and administrative costs eased, and the reported quarterly profit is an accounting artifact of discontinued operations on the plant sale colliding with a large non-cash extinguishment charge on the expanded ZYNYZ royalty sale. Pro forma liquidity of $327 million, including cash already on the June balance sheet plus Bora, Sanofi, and Gilead receipts, is the real balance-sheet event. Listed equity still prices the wholly owned pipeline at little more than option value after remaining lease-like liabilities. That discount is coherent only if the next clinical posters fail to show a competitive profile.
October's European oncology meeting is the first public look at whether the B7-H3 conjugate MGC026 can succeed where the prior B7-H3 program, vobramitamab duocarmazine, failed on lung toxicity. A clean expansion signal in head-and-neck cancer would justify treating the cash discount as a temporary mispricing. A noisy or toxic dataset would confirm that the company sold its last cash engine just as the replacement pipeline remains unproven. The live question is whether the plant sale bought enough time for the new payload to work, or merely postponed a thinner recapitalization.